Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 4
1956 10
1957 4
1958 6
1959 5
1960 7
1961 6
1962 1
1963 3
1964 2
1965 4
1966 6
1968 6
1969 1
1970 3
1972 3
1973 1
1974 1
1976 1
1977 1
1979 3
1981 2
1982 2
1983 3
1984 5
1985 7
1986 7
1987 8
1988 3
1989 8
1990 6
1991 6
1992 5
1993 6
1994 8
1995 5
1996 6
1997 12
1998 9
1999 6
2000 14
2001 5
2002 5
2003 11
2004 5
2005 9
2006 12
2007 9
2008 7
2009 22
2010 22
2011 25
2012 15
2013 18
2014 19
2015 14
2016 18
2017 8
2018 15
2019 11
2020 26
2021 26
2022 29
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

510 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Dimopoulos MA, et al. Among authors: baldini l. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. Lancet Oncol. 2021. PMID: 34087126 Clinical Trial.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Dimopoulos MA, et al. Among authors: baldini l. Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1. Lancet Haematol. 2023. PMID: 37793772 Clinical Trial.
Polarized x-rays from a magnetar.
Taverna R, Turolla R, Muleri F, Heyl J, Zane S, Baldini L, González-Caniulef D, Bachetti M, Rankin J, Caiazzo I, Di Lalla N, Doroshenko V, Errando M, Gau E, Kırmızıbayrak D, Krawczynski H, Negro M, Ng M, Omodei N, Possenti A, Tamagawa T, Uchiyama K, Weisskopf MC, Agudo I, Antonelli LA, Baumgartner WH, Bellazzini R, Bianchi S, Bongiorno SD, Bonino R, Brez A, Bucciantini N, Capitanio F, Castellano S, Cavazzuti E, Ciprini S, Costa E, De Rosa A, Del Monte E, Di Gesu L, Di Marco A, Donnarumma I, Dovčiak M, Ehlert SR, Enoto T, Evangelista Y, Fabiani S, Ferrazzoli R, Garcia JA, Gunji S, Hayashida K, Iwakiri W, Jorstad SG, Karas V, Kitaguchi T, Kolodziejczak JJ, La Monaca F, Latronico L, Liodakis I, Maldera S, Manfreda A, Marin F, Marinucci A, Marscher AP, Marshall HL, Matt G, Mitsuishi I, Mizuno T, Ng SC, O'Dell SL, Oppedisano C, Papitto A, Pavlov GG, Peirson AL, Perri M, Pesce-Rollins M, Pilia M, Poutanen J, Puccetti S, Ramsey BD, Ratheesh A, Romani RW, Sgrò C, Slane P, Soffitta P, Spandre G, Tavecchio F, Tawara Y, Tennant AF, Thomas NE, Tombesi F, Trois A, Tsygankov SS, Vink J, Wu K, Xie F. Taverna R, et al. Among authors: baldini l. Science. 2022 Nov 11;378(6620):646-650. doi: 10.1126/science.add0080. Epub 2022 Nov 3. Science. 2022. PMID: 36356124
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
Cattaneo D, Bucelli C, Marchetti A, Lionetti M, Fermo E, Bellani V, De Magistris C, Maeda A, Marella A, Primignani M, Consonni D, Gianelli U, Neri A, Baldini L, Bolli N, Iurlo A. Cattaneo D, et al. Among authors: baldini l. Ann Hematol. 2023 Jun;102(6):1409-1420. doi: 10.1007/s00277-023-05217-2. Epub 2023 Apr 20. Ann Hematol. 2023. PMID: 37079068 Review.
What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. Bolli N, et al. Among authors: baldini l. J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421. J Clin Med. 2021. PMID: 33499196 Free PMC article. Review.
Calixarene-based multivalent ligands.
Baldini L, Casnati A, Sansone F, Ungaro R. Baldini L, et al. Chem Soc Rev. 2007 Feb;36(2):254-66. doi: 10.1039/b603082n. Epub 2006 Nov 6. Chem Soc Rev. 2007. PMID: 17264928 Review.
MIS-C Treatment: Is IVIG Always Necessary?
Licciardi F, Baldini L, Dellepiane M, Covizzi C, Mogni R, Pruccoli G, Orsi C, Rabbone I, Parodi E, Mignone F, Montin D. Licciardi F, et al. Among authors: baldini l. Front Pediatr. 2021 Nov 3;9:753123. doi: 10.3389/fped.2021.753123. eCollection 2021. Front Pediatr. 2021. PMID: 34805048 Free PMC article.
510 results